GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (AMEX:ARMP) » Definitions » ROE %

Armata Pharmaceuticals (Armata Pharmaceuticals) ROE % : 0.00% (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Armata Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Armata Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2023 was $-79.39 Mil. Armata Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $-22.23 Mil. Therefore, Armata Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Armata Pharmaceuticals's ROE % or its related term are showing as below:

ARMP' s ROE % Range Over the Past 10 Years
Min: -3439.35   Med: -139.87   Max: Negative Equity
Current: -1039.24

During the past 13 years, Armata Pharmaceuticals's highest ROE % was Negative Equity%. The lowest was -3,439.35%. And the median was -139.87%.

ARMP's ROE % is ranked worse than
97.94% of 1360 companies
in the Biotechnology industry
Industry Median: -44.015 vs ARMP: -1039.24

Armata Pharmaceuticals ROE % Historical Data

The historical data trend for Armata Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armata Pharmaceuticals ROE % Chart

Armata Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -168.89 -132.62 -104.65 -120.10 -3,439.35

Armata Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -101.05 -198.06 -68.23 -3,689.33 -

Competitive Comparison of Armata Pharmaceuticals's ROE %

For the Biotechnology subindustry, Armata Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Armata Pharmaceuticals's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's ROE % falls into.



Armata Pharmaceuticals ROE % Calculation

Armata Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-69.045/( (36.08+-32.065)/ 2 )
=-69.045/2.0075
=-3,439.35 %

Armata Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-79.388/( (-12.386+-32.065)/ 2 )
=-79.388/-22.2255
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Armata Pharmaceuticals  (AMEX:ARMP) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-79.388/-22.2255
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-79.388 / 0)*(0 / 105.562)*(105.562 / -22.2255)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-79.388/-22.2255
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-79.388 / -79.388) * (-79.388 / -38.316) * (-38.316 / 0) * (0 / 105.562) * (105.562 / -22.2255)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 2.0719 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Armata Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Armata Pharmaceuticals (Armata Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4503 Glencoe Avenue, Marina del Rey, CA, USA, 90292
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Executives
Richard Rychlik officer: Corporate Controller and PFO 5005 MCCONNELL AVENUE, LOS ANGELES CA 90066
Deborah Birx director, officer: Chief Executive Officer 3300 LOWELL STREET NW, WASHINGTON DC 20008
Julianne Averill officer: Chief Financial Officer 361 NEWBURY STREET, SUITE 500, BOSTON MA 02115
Erin Butler officer: Vice President,Finance & Admin 4375 LOMA RIVIERA COURT, SAN DIEGO CA 92110
Theravance Inc director, 10 percent owner 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Innoviva Strategic Opportunities Llc director, 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801
Robin Kramer director 999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109
Steven Robert Martin officer: Chief Financial Officer 11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Curnock Cook director TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
Michael S Perry director C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Todd C. Peterson director C/O ARMATA PHARMACEUTICALS, INC., 4503 GLENCOE AVENUE, MARINA DEL REY CA 90292
H Stewart Parker director

Armata Pharmaceuticals (Armata Pharmaceuticals) Headlines